Trial Profile
A Study to Evaluate Changes in Phosphate Regulating Factors in Patients with Advanced Renal Cell Carcinoma (RCC) Treated with Sorafenib (Nexavar).
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2010
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 02 Aug 2010 New trial record